초록

방사선 폐섬유화에 의한 폐손상의 진단 및 치료가 가능한 나노입자를 개발하고 이를 동물 모델에서 평가하여 방사선 유래성 폐질환에 적용 가능한 테라노스틱 기술을 개발함.

(출처 : 보고서 요약서 3p)

Abstract ▼

II. Purpose
The aim of this project is to develop nanoparticles capable of diagnosis and treatment of pulmonary damage by radiation- induced lung fibrosis and to evaluate them in animal models to establish theranostic technology applicable to radiation-induced lung diseases

III. Contents

II. Purpose
The aim of this project is to develop nanoparticles capable of diagnosis and treatment of pulmonary damage by radiation- induced lung fibrosis and to evaluate them in animal models to establish theranostic technology applicable to radiation-induced lung diseases

III. Contents
1st year: Lung-specific delivery of nanoparticles made of biocompatible materials
● Preparation of biocompatible nanoparticles for lung delivery
● Optimization of the conditions for lung delivery of the nanoparticles
2nd year: Development of imaging technology for radiation-induced pulmonary fibrosis
● Preparation of reactive oxygen species (ROS)-responsive probes
● Nano-formulation of the probes using the nanoparticles developed in the 1st Year
● Establishment of conditions to image radiation-induced pulmonary fibrosis using the nanoparticulate probes responsive to fibrosis-related ROS.
3rd year: Development of theranostic technology for radiation-induced pulmonary fibrosis by combining the imaging and the treatment methods
● Development of siRNAs (ASOs) that inhibit radiation-induced pulmonary fibrosis
● Nano-formulation of siRNA (ASO) using the nanoparticles developed in the 1st year and development of therapeutic means for radiation-induced pulmonary fibrosis.
● Development of nanoparticle-based theranostic technology for simultaneous imaging and treatment of pulmonary fibrosis.

IV. Results
1) 1 year: Lung-specific delivery of nanoparticles made of biocompatible materials
● Prepared biocomaptible polymer microparticle and confirmation of its lung-specific accumulation
● Produced various sizes of nano-/microparticles by using RCA techqniue and optimized the particle for lung-specific accumulation
● Designed ROS-sensitive chemiluminescence nanoprobe for diagnosis of pulmonary fibrosis
2) 2 year: Development of imaging technology for radiation-induced pulmonary fibrosis
● Optimized ROS-sensitive chemiluminescence nanoprobe in pulmonary fibrois animal model
● Prepared MMP12-sensitive fluorescence peptide probe and validation of the probe in pulmonary fibrosis animal model
● Designed antisense oligonucleotide (ASO) of targeting TGF-β for treating pulmonary fiboris and prepared it to a nanoparticle form using RCA method
● Combined ASO nanoparticle with biocompatible peptide and optimized the lung-targeting condition
3) 3 year: Development of theranostic technology for radiation-induced pulmonary fibrosis by combining the imaging and the treatment methods
● Demonstrated real-time diagnosis of ROS-sensitive chemiluminescence nanoprobe by co-injection of chemotherapetuics
● Validated MMP12-sensitive fluorescence peptide probe in radiation-induced lung fibrosis animal model
● Confirmed no systemic toxicity of ASO/peptide nanoparticle and alleviation of fibrosis in pulmonary fibrosis animal model

V.Expected contributions
● The lung-targeted delivery can be used to selectively and effectively deliver therapeutic agents for various lung diseases, providing low side-effect and high efficacy.
● The output of the project can be utilized to minimize the side effects of pulmonary injury caused by lung radiotherapy.
● It also provides a technique to diagnose damages caused by fibrosis at the molecular level by imaging ROS associated with fibrosis not only in lung but also in other tissues.

(출처 : SUMMARY 5p)